Opendata, web and dolomites

VOILA SIGNED

Validation of Innovative Lipopeptide Antibiotics

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

Project "VOILA" data sheet

The following table provides information about the project.

Coordinator
UNIVERSITEIT LEIDEN 

Organization address
address: RAPENBURG 70
city: LEIDEN
postcode: 2311 EZ
website: www.universiteitleiden.nl

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Netherlands [NL]
 Total cost 150˙000 €
 EC max contribution 150˙000 € (100%)
 Programme 1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC))
 Code Call ERC-2018-PoC
 Funding Scheme ERC-POC
 Starting year 2019
 Duration (year-month-day) from 2019-04-01   to  2020-09-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    UNIVERSITEIT LEIDEN NL (LEIDEN) coordinator 150˙000.00

Map

 Project objective

Antibiotic resistance presents a growing threat to global health. The emergence of the superbugs is alarming: at current rates of increase, and without new intervention strategies, antibiotic resistance could cause a staggering 10 million deaths/year worldwide by 2050. Therefore, new approaches need to be developed to combat antibiotic resistance, particularly for the WHO’s priority pathogens which include the so-called ESKAPE family of dangerous drug-resistant bacteria.

Recently, we developed a novel technology platform comprising a set of methodologies to semisynthetically modify the natural antibiotic nisin. In doing so we generated novel lipopeptide antibiotics with a much higher in vivo stability than the parent compound. These semisynthetic antibiotics possess a lipid II-mediated mode of action similar to nisin, which sets them apart from any current clinically-used antibiotic. During my ERC CoG, we have significantly improved these compounds, i.e. increased their antimicrobial activity and eliminated undesired haemolytic effects. Importantly, preliminary data shows that these antibiotics have a lower propensity to lose their potency due to antibiotic resistance development. I propose that these innovative lipopeptide antibiotics present a significant step forward in addressing the alarming threat of antibiotic resistance. However, to establish their commercial viability and broad applicability, the efficacy and preliminary safety of the new compounds need to be addressed. This can best be achieved via a PK/PD proof of concept study in appropriate animal models along with with a detailed evaluation of the business opportunity.

The main objective of VOILA is therefore to establish both the technical feasibility and commercial viability of an entirely new class of lipopeptide antibiotics that is enabled by our innovative technology platform.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "VOILA" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "VOILA" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.1.)

PROGRESS (2019)

The Enemy of the Good: Towards a Theory of Moral Progress

Read More  

DISINTEGRATION (2019)

The Mass Politics of Disintegration

Read More  

FICOMOL (2019)

Field Control of Cold Molecular Collisions

Read More